Real Hope For Cancer Patients | Precision Biologics

UNIQUE DISCOVERY PLATFORM

realize our potential

LEARN MORE

We have a platform of patient tumor
derived anticancer vaccines.

THERAPEUTICS

leaders in biotherapeutics

LEARN MORE

Our unique platform, combined with breakthroughs in biotechnology, enable us to produce targeted antibodies that weren’t possible just a few years ago.

COMPANION DIAGNOSTICS

explore our program

LEARN MORE

Our monoclonal antibodies are designed to target the tumor without harming healthy cells.

Precision Biologics is dedicated to improving the lives of cancer patients through its innovative therapeutic and diagnostic products.

Precision Biologics, Inc. and National Cancer Institute Collaborators Deliver Poster Presentation at the ASCO Annual Meeting June 5, 2022

DATE: June 5, 2022

Dr. Philip M. Arlen gives Immunotherapy Section Opening Keynote at Festival of Biologics, San Diego, March 9, 2022

DATE: March 9, 2022

Dr. Philip M. Arlen gives scientific presentation at Biomarkers UK: In-Person, November 8, 2021, Manchester, UK

DATE: November 8, 2021

Phase II Clinical Trial NEO-201 in Combination with Pembrolizumab Detailed Study Information

DATE: October 29, 2021

Precision Biologics to Deliver two Oral Presentations on our Clinical and Scientific Programs at 6th Annual Neoantigen Based Therapies Summit, October 26-28th, Digital Event

DATE: October 28, 2021

Precision Biologics Commences Phase 2 Clinical Trial using NEO-201 and Pembrolizumab as a 2nd line Therapy in Patients with Solid Tumors

DATE: October 14, 2021

# of people living with cancer in the US

annual # of new cases of cancer in the US

annual # of deaths from cancer in the US